A Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ANXV Administered as an Intravenous Infusion to Healthy Male Subjects
Latest Information Update: 21 May 2022
At a glance
- Drugs Dianexin (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; First in man
- Sponsors Annexin Pharmaceuticals
- 12 May 2022 Status changed from recruiting to completed.
- 28 Apr 2021 New trial record